|
Goodwill and intangible assets (Tables)
|
12 Months Ended |
|
Jul. 31, 2012
|
| Schedule of Goodwill [Table Text Block] |
The Company’s change in the net carrying amount of
goodwill by business segment is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Enzo Life
Sciences
|
|
Enzo
Clinical
Labs
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
August 1, 2010
|
|
$
|
17,491
|
|
$
|
7,452
|
|
$
|
24,943
|
|
|
Additional purchase price
consideration
|
|
|
1,150
|
|
|
—
|
|
|
1,150
|
|
|
Foreign currency
translation
|
|
|
1,280
|
|
|
—
|
|
|
1,280
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
July 31, 2011
|
|
|
19,921
|
|
|
7,452
|
|
|
27,373
|
|
|
Foreign currency
translation
|
|
|
(1,083
|
)
|
|
—
|
|
|
(1,083
|
)
|
|
Impairment charge
|
|
|
(18,838
|
)
|
|
—
|
|
|
(18,838
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
July 31, 2012
|
|
$
|
—
|
|
$
|
7,452
|
|
$
|
7,452
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Indefinite-Lived Intangible Assets [Table Text Block] |
The Company’s change in the net carrying amount of
intangible assets, all in the Life Sciences segment is as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
|
|
Accumulated
Amortization
|
|
Net
|
|
|
|
|
|
|
|
|
|
|
|
August 1, 2010
|
|
$
|
33,940
|
|
|
(13,572
|
)
|
|
20,368
|
|
|
Amortization expense
|
|
|
—
|
|
|
(1,507
|
)
|
|
(1,507
|
)
|
|
Foreign currency
translation
|
|
|
898
|
|
|
226
|
|
|
1,124
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
July 31, 2011
|
|
|
34,838
|
|
|
(14,853
|
)
|
|
19,985
|
|
|
Amortization expense
|
|
|
—
|
|
|
(1,660
|
)
|
|
(1,660
|
)
|
|
Foreign currency
translation
|
|
|
(1,232
|
)
|
|
389
|
|
|
(843
|
)
|
|
Trademark impairment
charge
|
|
|
(5,702
|
)
|
|
—
|
|
|
(5,702
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
July 31, 2012
|
|
$
|
27,904
|
|
$
|
(16,124
|
)
|
$
|
11,780
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
July 31, 2012
|
|
July 31, 2011
|
|
|
|
|
|
|
|
|
|
|
|
Gross
|
|
Accumulated
Amortization
|
|
Net
|
|
Gross
|
|
Accumulated
Amortization
|
|
Net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finite-lived intangible
assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patents
|
|
$
|
11,027
|
|
$
|
(10,439
|
)
|
$
|
588
|
|
$
|
11,027
|
|
$
|
(10,278
|
)
|
$
|
749
|
|
|
Customer
relationships
|
|
|
12,304
|
|
|
(4,356
|
)
|
|
7,948
|
|
|
12,789
|
|
|
(3,472
|
)
|
|
9,317
|
|
|
Website and acquired
content
|
|
|
1,019
|
|
|
(874
|
)
|
|
145
|
|
|
1,063
|
|
|
(748
|
)
|
|
315
|
|
|
Licensed technology and
other
|
|
|
485
|
|
|
(300
|
)
|
|
185
|
|
|
649
|
|
|
(355
|
)
|
|
294
|
|
|
Trademarks, gives effect
for impairment charge and reclassification to
finite-lived as of May 1, 2012
|
|
|
3,069
|
|
|
(155
|
)
|
|
2,914
|
|
|
9,310
|
|
|
—
|
|
|
9,310
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
27,904
|
|
$
|
(16,124
|
)
|
$
|
11,780
|
|
$
|
34,838
|
|
$
|
(14,853
|
)
|
$
|
19,985
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At July 31, 2012 information with respect to the intangibles
acquired is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Useful life
assigned
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minimum
|
|
Maximum
|
|
|
|
Weighted average
remaining useful life
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer
relationships
|
|
|
8
|
|
15
|
|
|
|
8 years
|
|
Trademarks
|
|
|
|
|
|
|
5
|
|
5 years
|
|
Other intangibles
|
|
|
4
|
|
5
|
|
|
|
2 years
|
|
| Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] |
Estimated amortization expense related to these finite-lived
intangible assets for the five succeeding fiscal years ending
July 31 is as follows:
|
|
|
|
|
|
|
|
|
2013
|
|
$
|
1,911
|
|
|
|
2014
|
|
|
1,796
|
|
|
|
2015
|
|
|
1,755
|
|
|
|
2016
|
|
|
1,729
|
|
|
|
2017
|
|
|
1,515
|
|
|